吉非替尼治疗69例老年肺腺癌的临床分析  

Clinic outcome of gefitinib in sixty-nine elderly patients with lung adenocarcinoma.

作　　者：王燕[1] 张湘茹[1] 王彬[1] 王子平[1] 储大同[1] 孙燕[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤研究所肿瘤医院内科,北京100021

出　　处：《中国肺癌杂志》2008年第1期137-141,共5页Chinese Journal of Lung Cancer

摘　　要：背景和目的探讨上皮生长因子受体(EGFR)酪氨酸激酶抑制剂(EGFR-TKI)吉非替尼(Gefitinib,Iressa,易瑞沙)治疗老年晚期肺腺癌的疗效及安全性。方法对2002年10月至2006年12月在中国医学科学院肿瘤医院治疗的69例65岁以上患者的临床特点、治疗效果及生存时间进行了回顾性分析。所有患者均口服吉非替尼250 mg/天,直到病变进展或不能耐受。结果吉非替尼总有效率24.6%,疾病控制率88.4%,中位生存时间15个月,1年生存率62.2%。年龄<75岁,不吸烟,一线治疗患者的有效率明显高于≥75岁,吸烟,二线以上治疗的患者。女性,肺泡细胞癌和不吸烟患者的生存时间优于男性,腺癌和吸烟患者。吉非替尼的不良反应较轻,主要表现为轻度皮疹和腹泻。结论吉非替尼治疗老年晚期肺腺癌安全有效。Background and Objective To evaluate the efficacy and safety of gefitinib, an orally active epidermal growth factor receptor tyrosine kinase inhibitor（EGFR-TKI）, in elderly patients with other types of adenocarcinoma. Methods The clinical characteristics, response of treatment and survival were retrospectively reviewed in sixty-nine elderly patients （≥65 years）. All these patients received gefitinib 250mg/d in Cancer Institute （ Hospital ）, Chinese Aacademy of Medical Sciences until disease progression or toxicities not tolerated by patient. Resuits Overall response rate and disease controlled rate （DCR） of gefitinib were 24.6% and 88.4% respectively. The median survival time was 15 months. One year survival was 62.2%. The response rate of gefitinib were significantly higher in patients less than 75-year-old, non-smoker and first-line treatment group than in patients above 75-year-old, smoker and second-line or third-line treatment. Furthermore, the overall survival times were signifi- cantly longer in patients of Bronchioloalveolar carcinoma, female and nonsmokers than patients with adenocarcinoma, and male and smokers. Rash and diarrhea were the most common adverse events （AEs） , but usually were mild. Conclusion Gefitinib is effective and safe in elderly patients with advanced adenocarcinomas of the lung.

关 键 词：非小细胞肺癌 老年患者 吉非替尼 腺癌 

分 类 号：R734.2[医药卫生—肿瘤]